CCR6 Is a Predicting Biomarker of Radiosensitivity and Potential Target of Radiosensitization in Rectal Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose This study aimed to explore the functions and mechanisms of C-C motif chemokine receptor 6 (CCR6), a gene associated with progression and metastasis of colorectal cancer (CRC), in radiosensitivity of rectal cancer (RC). Materials and Methods RNA sequencing and immunohistochemical analysis on CCR6 expression were performed in pretreatment tissues of RC patients exhibiting different therapeutic effects of radiotherapy. Colonogenic survival assay was conducted in different CRC cell lines to assess their radiosensitivity. And the impact of CCR6 expression on radiosensitivity was validated through RNA interference. The DNA damage repair (DDR) abilities of cell lines with different CCR6 expression were evaluated through immunofluorescence-based H2AX quantification. Results The CCR6 mRNA level was higher in patients without pathologic complete remission (pCR) than in those with pCR (fold changed, 2.11; p=0.004). High-level expression of CCR6 protein was more common in the bad responders than in the good responders (76.3% vs. 37.5%, p < 0.001). The CRC cell lines with higher CCR6 expression (LoVo and sw480) appeared to be more radioresistant, compared with the sw620 cell line which had lower CCR6 expression. CCR6 knockdown made the LoVo cells more sensitive to ionizing radiation (sensitization enhancement ratio, 1.738; p < 0.001), and decreased their DDR efficiency. Conclusion CCR6 might affect the RC radiosensitivity through DDR process. These findings supported CCR6 as a predicting biomarker of radiosensitivity and a potential target of radiosensitization for RC patients.
Abstract
Purpose This study aimed to explore the functions and mechanisms of C-C motif chemokine receptor 6 (CCR6), a gene associated with progression and metastasis of colorectal cancer (CRC), in radiosensitivity of rectal cancer (RC). Materials and Methods RNA sequencing and immunohistochemical analysis on CCR6 expression were performed in pretreatment tissues of RC patients exhibiting different therapeutic effects of radiotherapy. Colonogenic survival assay was conducted in different CRC cell lines to assess their radiosensitivity. And the impact of CCR6 expression on radiosensitivity was validated through RNA interference. The DNA damage repair (DDR) abilities of cell lines with different CCR6 expression were evaluated through immunofluorescence-based H2AX quantification. Results The CCR6 mRNA level was higher in patients without pathologic complete remission (pCR) than in those with pCR (fold changed, 2.11; p=0.004). High-level expression of CCR6 protein was more common in the bad responders than in the good responders (76.3% vs. 37.5%, p < 0.001). The CRC cell lines with higher CCR6 expression (LoVo and sw480) appeared to be more radioresistant, compared with the sw620 cell line which had lower CCR6 expression. CCR6 knockdown made the LoVo cells more sensitive to ionizing radiation (sensitization enhancement ratio, 1.738; p < 0.001), and decreased their DDR efficiency. Conclusion CCR6 might affect the RC radiosensitivity through DDR process. These findings supported CCR6 as a predicting biomarker of radiosensitivity and a potential target of radiosensitization for RC patients.
참고문헌 (30)
- Chen W, "Cancer statistics in China, 2015", CA Cancer J Clin, 66, pp.115~132 (2016)
- 박혜진, "Patterns of Rectal Cancer Radiotherapy Adopting Evidence-Based Medicine: An Analysis of the National Database from 2005 to 2016", Cancer Research and Treatment, 50(3), pp.975~983 (2018), 대한암학회
- Fokas E, "Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO", ARO, J Clin Oncol, pp.2014, 32[DOI]
- Trakarnsanga A, "Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment", J Natl Cancer Inst, 106, pp.dju248~ (2014)
- Morgan MA, "Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways", Clin Cancer Res, 21, pp.2898~2904 (2015)
- Barker HE, "The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence", Nat Rev Cancer, 15, pp.409~425 (2015)
- Zlotnik A, "Homeostatic chemokine receptors and organ-specific metastasis", Nat Rev Immunol, 11, pp.597~606 (2011)
- Ghadjar P, "Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer", J Clin Oncol, 24, pp.1910~1916 (2006)
- Kapur N, "CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition", Br J Cancer, 114, pp.1343~1351 (2016)
- Nandi B, "CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis", PLoS One, 9, pp.e97566~ (2014)
- Frick VO, "Chemokine", chemokine receptor pair CCL20, World J Gastroenterol, pp.2016, 22[DOI]
- Hu L, "UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy", Oncogene, 36, pp.1145~1156 (2017)
- Ko JC, "Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells", Biochem Pharmacol, 105, pp.91~100 (2016)
- Marampon F, "Hypoxia sustains glioblastoma radioresistance through ERKs", DNA-PKcs, Int J Oncol, pp.2014, 44[DOI]
- Mandric I, "Fast bootstrapping-based estimation of confidence intervals of expression levels and differential expression from RNA-Seq data", Bioinformatics, 33, pp.3302~3304 (2017)
- Tripathi S, "Meta- and orthogonal integration of influenza "OMICs" data defines a role for UBR4 in virus budding", Cell Host Microbe, 18, pp.723~735 (2015)
- Chen DL, "Long noncoding RNA XIST expedites metastasis and modulates epithelial-mesenchymal transition in colorectal cancer", Cell Death Dis, 8, pp.e3011~ (2017)
- Cerda MB, "Silencing peroxiredoxin-2 sensitizes human colorectal cancer cells to ionizing radiation and oxaliplatin", Cancer Lett, 388, pp.312~319 (2017)
- Untergasser A, "Primer3: new capabilities and interfaces", Nucleic Acids Res, 40, pp.e115~ (2012)
- Tu Z, "BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro", Radiat Oncol, 10, pp.123~ (2015)
- Kleiner RE, "Chemical proteomics reveals a gammaH2AX-53BP1 interaction in the DNA damage response", Nat Chem Biol, 11, pp.807~814 (2015)
- Chin CC, "Interleukin-17 induces CC chemokine receptor 6 expression and cell migration in colorectal cancer cells", J Cell Physiol, 230, pp.1430~1437 (2015)
- Maier P, "Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization", Int J Mol Sci, 17, pp.E102~ (2016)
- Jong-Soo Lee, "Activation of ATM-dependent DNA Damage Signal Pathway by a Histone Deacetylase Inhibitor, Trichostatin A", Cancer Research and Treatment, 39(3), pp.125~130 (2007), 대한암학회
- Moon SH, "Wild-type p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair", J Biol Chem, 285, pp.12935~12947 (2010)
- Zhu Y, "Long non-coding RNA LOC572558 inhibits bladder cancer cell proliferation and tumor growth by regulating the AKT-MDM2-p53 signaling axis", Cancer Lett, 380, pp.369~374 (2016)
- Mendoza MC, "The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation", Trends Biochem Sci, 36, pp.320~328 (2011)
- Sato A, "MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis", Stem Cells, 29, pp.1942~1951 (2011)
- Sun Y, "Tumor microenvironment and cancer therapy resistance", Cancer Lett, 380, pp.205~215 (2016)
- Trautmann F, "CXCR4 as biomarker for radioresistant cancer stem cells", Int J Radiat Biol, 90, pp.687~699 (2014)